207 related articles for article (PubMed ID: 36081350)
1. MAP7D2 reduces CD8
Wu Q; Yue X; Liu H; Zhu Y; Ke H; Yang X; Yin S; Li Z; Zhang Y; Hu T; Lan P; Wu X
Mol Ther; 2023 Jan; 31(1):90-104. PubMed ID: 36081350
[TBL] [Abstract][Full Text] [Related]
2. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.
Quan Y; He J; Zou Q; Zhang L; Sun Q; Huang H; Li W; Xie K; Wei F
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597850
[TBL] [Abstract][Full Text] [Related]
4. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
5. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer.
Shi R; Zhou X; Pang L; Wang M; Li Y; Chen C; Ning H; Zhang L; Yue G; Qiu L; Zhao W; Qi Y; Wu Y; Gao Y
Cancer Immunol Immunother; 2023 Apr; 72(4):985-1001. PubMed ID: 36251028
[TBL] [Abstract][Full Text] [Related]
7. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
8. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.
Li YY; Wang XY; Li Y; Wang XM; Liao J; Wang YZ; Hong H; Yi W; Chen J
Cell Oncol (Dordr); 2023 Jun; 46(3):777-791. PubMed ID: 36920728
[TBL] [Abstract][Full Text] [Related]
10. Musashi-2 potentiates colorectal cancer immune infiltration by regulating the post-translational modifications of HMGB1 to promote DCs maturation and migration.
Meng X; Na R; Peng X; Li H; Ouyang W; Zhou W; You X; Li Y; Pu X; Zhang K; Xia J; Wang J; Tang H; Zhuang G; Peng Z
Cell Commun Signal; 2024 Feb; 22(1):117. PubMed ID: 38347600
[TBL] [Abstract][Full Text] [Related]
11. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
Wang D; Zhang H; Xiang T; Wang G
Front Immunol; 2021; 12():762341. PubMed ID: 34721435
[TBL] [Abstract][Full Text] [Related]
12. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
14. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.
Liu F; Zhang H; Shen D; Wang S; Ye Y; Chen H; Pang X; Song Q; He P
J Gastroenterol; 2014 Mar; 49(3):419-26. PubMed ID: 23604623
[TBL] [Abstract][Full Text] [Related]
15. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
16. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.
Zhai J; Chen H; Wong CC; Peng Y; Gou H; Zhang J; Pan Y; Chen D; Lin Y; Wang S; Kang W; To KF; Chen Z; Nie Y; He HH; Sung JJ; Yu J
Gastroenterology; 2023 Aug; 165(2):445-462. PubMed ID: 37169182
[TBL] [Abstract][Full Text] [Related]
17. Galectin-7 Induction by EHMT2 Inhibition Enhances Immunity in Microsatellite Stability Colorectal Cancer.
Sun L; Liu R; Wu ZJ; Liu ZY; Wan AH; Yan S; Liu C; Liang H; Xiao M; You N; Lou Y; Deng Y; Bu X; Chen D; Huang J; Zhang X; Kuang DM; Wan G
Gastroenterology; 2024 Mar; 166(3):466-482. PubMed ID: 38065340
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer.
Wu C; Shao Y; Gu W
Clin Transl Oncol; 2023 Jul; 25(7):1916-1928. PubMed ID: 36717514
[TBL] [Abstract][Full Text] [Related]
19. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
Guo L; Wang C; Qiu X; Pu X; Chang P
Front Immunol; 2020; 11():1052. PubMed ID: 32547556
[TBL] [Abstract][Full Text] [Related]
20. Centrosomal Protein 55 (CEP55) Drives Immune Exclusion and Resistance to Immune Checkpoint Inhibitors in Colorectal Cancer.
Wangmo D; Gates TJ; Zhao X; Sun R; Subramanian S
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
